Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.66 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.66 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402636 | 0.86 | ACHE (0.55) | DRD4SLC6A12SLC6A13MCHR1 | |
| SCHEMBL61347 | 0.86 | DRD4 (0.66) | DRD4SLC6A12SLC6A13 | |
| SCHEMBL61628 | 0.86 | DRD4 (0.78) | DRD4SLC6A12SLC6A13MCHR1 | |
| SCHEMBL2388851 | 0.82 | KMT2A (0.74) | DRD4SLC6A12SLC6A13MCHR1 | |
| SCHEMBL4405711 | 0.81 | ACHE (0.52) | DRD4SLC6A12SLC6A13MCHR1 | |
| SCHEMBL62036 | 0.81 | DRD4 (0.69) | DRD4SLC6A12SLC6A13MCHR1 | |
| SCHEMBL12226805 | 0.81 | OPRK1 (0.70) | DRD4SLC6A12SLC6A13MCHR1 | |
| SCHEMBL4405714 | 0.78 | ACHE (0.46) | MCHR1 | |
| SCHEMBL62398 | 0.78 | DRD4 (0.85) | DRD4SLC6A12SLC6A13ROCK2ROCK1 | |
| SCHEMBL3665894 | 0.78 | PRKAA2 (0.56) | DRD4SLC6A12SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | DRD4 2946/4885SLC6A12 4061/4885SLC6A13 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.